Philippe Moris

4.2k total citations
54 papers, 2.8k citations indexed

About

Philippe Moris is a scholar working on Epidemiology, Immunology and Infectious Diseases. According to data from OpenAlex, Philippe Moris has authored 54 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 25 papers in Immunology and 18 papers in Infectious Diseases. Recurrent topics in Philippe Moris's work include Influenza Virus Research Studies (12 papers), Malaria Research and Control (12 papers) and Respiratory viral infections research (10 papers). Philippe Moris is often cited by papers focused on Influenza Virus Research Studies (12 papers), Malaria Research and Control (12 papers) and Respiratory viral infections research (10 papers). Philippe Moris collaborates with scholars based in Belgium, United States and United Kingdom. Philippe Moris's co-authors include Opokua Ofori‐Anyinam, Emmanuel Hanon, Geert Leroux‐Roels, Joe Cohen, Frédéric Clément, Erik Jongert, Francis Dessy, Marie‐Ange Demoitié, Isabel Leroux‐Roels and Sandro Giannini and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Philippe Moris

53 papers receiving 2.7k citations

Peers

Countries citing papers authored by Philippe Moris

Since Specialization

Citations

This map shows the geographic impact of Philippe Moris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Moris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Moris more than expected).

Fields of papers citing papers by Philippe Moris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Moris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Moris. The network helps show where Philippe Moris may publish in the future.

Co-authorship network of co-authors of Philippe Moris

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Moris. A scholar is included among the top collaborators of Philippe Moris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Moris. Philippe Moris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults 2024 ·Vaccines ·(unknown), Isabel Leroux‐Roels, Jacques Bruhwyler, Nicola Groth, (unknown), Yorick Janssens, (unknown), Fien De Boever, (unknown), Philippe Moris, (unknown), Geert Leroux–Roels, (unknown)	2
2	Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults 2022 ·npj Vaccines ·Heather Friberg, (unknown), Amanda M. Kong, Leyi Lin, Luis Javier Martínez-González, Alexander C. Schmidt, Robert Paris, Richard G. Jarman, Clemente Díaz, Stephen J. Thomas, Philippe Moris, Jeffrey R. Currier	7
3	First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector–Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults 2019 ·Clinical Infectious Diseases ·Paola Cicconi, Claire Jones, (unknown), Laura Silva-Reyes, Paul Klenerman, Catherine de Lara, Claire Hutchings, Philippe Moris, Michel Janssens, Laurence Fissette, (unknown), Amanda Leach, (unknown), Ilse Dieussaert, Matthew D. Snape	43
4	First-in-human randomized study to assess the safety and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine based on ChAd155 viral vector expressing RSV viral proteins F, N and M2-1 in healthy adults. 2019 ·Clinical Infectious Diseases ·Paola Cicconi, Claerwen M. Jones, (unknown), Laura Silva-Reyes, Paul Klenerman, Catherine de Lara, Claire Hutchings, Philippe Moris, Michel Janssens, Laurence Fissette, (unknown), Amanda Leach, André Lopez, Ilse Dieussaert, (unknown)	4
5	Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial 2019 ·Vaccine ·Tom Wilkinson, Stuart Schembri, Christopher E. Brightling, Nawar Diar Bakerly, Keir Lewis, William MacNee, Lars Rombo, Jan Hedner, Martin Allen, Paul Walker, Iris De Ryck, Annaelisa Tasciotti, Daniela Casula, Philippe Moris, Marco Testa, Ashwani Kumar Arora	41
6	A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults 2016 ·Medicine ·Nagalingeswaran Kumarasamy, Selvamuthu Poongulali, Anne Bollaerts, Philippe Moris, (unknown), (unknown), Marie‐Ange Demoitié, Erik Jongert, Opokua Ofori‐Anyinam	35
7	Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines 2014 ·Human Vaccines & Immunotherapeutics ·Geert Leroux‐Roels, Isabel Leroux‐Roels, Frédéric Clément, Opokua Ofori‐Anyinam, Marc Lievens, Erik Jongert, Philippe Moris, W. Ripley Ballou, Joe Cohen	45
8	Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older 2014 ·BMC Infectious Diseases ·Robert B. Couch, José M. Bayas, (unknown), Innocent N. Mbawuike, (unknown), Carine Claeys, Mohamed El Idrissi, Caroline Hervé, Béatrice Laupèze, Lidia Oostvogels, Philippe Moris	28
9	Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy 2014 ·AIDS ·(unknown), Matthias Cavassini, R Audran, Anne‐Christine Thierry, Anne Bollaerts, Joe Cohen, Marie‐Ange Demoitié, Dawit A. Ejigu, Pascal Mettens, Philippe Moris, Opokua Ofori‐Anyinam, François Spertini	34
10	Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults 2014 ·Vaccine ·Kent E. Kester, D. Gray Heppner, Philippe Moris, Opokua Ofori‐Anyinam, Urszula Krzych, Nadia Tornieporth, Denise McKinney, Martine Delchambre, Christian F. Ockenhouse, Gérald Voss, Carolyn A. Holland, (unknown), W. Ripley Ballou, Joe Cohen	32
11	Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial 2014 ·Tuberculosis ·Olubukola T. Idoko, Olumuyiwa Owolabi, Patrick K. Owiafe, Philippe Moris, Aderonke Odutola, Anne Bollaerts, Ezra Olatunde Ogundare, Erik Jongert, Marie‐Ange Demoitié, Opokua Ofori‐Anyinam, Martin O. C. Ota	42
12	Long-term persistence of humoral and cellular immune responses induced by an AS03_A-adjuvanted H1N1 2009 influenza vaccine 2013 ·Human Vaccines & Immunotherapeutics ·Pierre Van Damme, (unknown), (unknown), Emmanuel Hanon, Philippe Moris, François Roman, Paul Gillard	9
13	Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials 2013 ·Vaccine ·Isabel Leroux‐Roels, Jeanne‐Marie Devaster, Geert Leroux‐Roels, Vincent Verlant, Isabelle Henckaerts, Philippe Moris, Philippe Hermand, Pascale Van Belle, Jan Poolman, Pierre Vandepapelière, Yves Horsmans	52
14	An assessment of prime‐boost vaccination schedules with AS03_A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults 2012 ·Influenza and Other Respiratory Viruses ·Paul Gillard, Adrian Caplanusi, Markus Knuf, François Roman, Karl Walravens, Philippe Moris, Mamadou Dramé, Tino F. Schwarz	28
15	The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: A randomized controlled phase I/II study 2012 ·Tuberculosis ·François Spertini, R Audran, (unknown), Opokua Ofori‐Anyinam, (unknown), Pierre Vandepapelière, Philippe Moris, Marie‐Ange Demoitié, Pascal Mettens, (unknown), (unknown), Erik Jongert, Joe Cohen, W. Ripley Ballou	42
16	Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells 2011 ·PLoS ONE ·Joanne M. Lumsden, Robert Schwenk, Lisa Rein, Philippe Moris, Michel Janssens, Opokua Ofori‐Anyinam, Joe Cohen, Kent E. Kester, D. Gray Heppner, Urszula Krzych	68
17	The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans 2009 ·Human Vaccines ·(unknown), (unknown), (unknown), Opokua Ofori‐Anyinam, (unknown), (unknown), Marguerite Koutsoukos, Philippe Moris, Daniel Cain, Marie‐Claude Dubois, Joe Cohen, W. Ripley Ballou	89
18	Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only 2006 ·Vaccine ·Sandro Giannini, Emmanuel Hanon, Philippe Moris, Maxime Vanmechelen, (unknown), Francis Dessy, Marc Fourneau, Brigitte Colau, (unknown), (unknown)	391
19	Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults 2004 ·Vaccine ·Pierre Vandepapelière, Barbara Rehermann, Marguerite Koutsoukos, Philippe Moris, Nathalie Garçon, Martine Wettendorff, Geert Leroux‐Roels	38
20	Comparison of three luminescent assays combined with a sandwich hybridization for the measurement of PCR-amplified human cytomegalovirus DNA 1997 ·Journal of Virological Methods ·Isabelle Alexandre, Nathalie Zammatteo, Philippe Moris, Françoise Brancart, José Remacle	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact